期刊文献+

替罗非班联合比索洛尔对冠心病介入治疗的疗效及对心功能的影响

Therapeutic effect of tirofiban combined bisoprolol in interventional treatment of CHD and its impact on cardiac function
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:探讨替罗非班联合比索洛尔对冠心病介入治疗的疗效及对患者心功能的影响。方法:选择我院收治的114例冠心病患者,随机均分替罗非班组(单纯应用替罗非班治疗),联合治疗组(替罗非班联合比索洛尔治疗),两组均持续两周用药。对比两组治疗前后实验室指标、心功能指标、心功能分级的改善情况以及主要不良心血管事件(MACE)发生率。结果:治疗后,与替罗非班组比较,联合治疗组血清氧化性谷胱甘肽(GSSG)[(30.4±5.5)μmol/L比(28.5±4.1)μmol/L]、高敏C反应蛋白(hsCRP)[(8.8±1.7)mg/L比(7.6±1.5)mg/L]水平均显著降低,一氧化氮(NO)[(52.7±13.5)μmol/L比(61.5±17.2)μmol/L]水平及心输出量(CO)[(4.3±0.7)L/min比(4.8±0.8)L/min]、每搏输出量(SV)[(77.6±10.7)ml比(88.1±11.2)ml]、左室射血分数(LVEF)[(55.4±11.2)%比(62.1±11.6)%]均显著提高(P<0.05或<0.01)。联合治疗组心功能分级的改善情况总有效率显著高于替罗非班组(96.49%比71.93%,P=0.001);MACE总发生率显著低于替罗非班组(10.53%比35.09%,P=0.002)。结论:替罗非班联合比索洛尔治疗冠心病,有助于减少心肌坏死,改善心功能,降低不良心血管事件的发生率,值得推广。 Objective:To explore therapeutic effect of tirofiban combined bisoprolol in interventional treatment of coronary heart disease(CHD)and its impact on cardiac function.Methods:A total of 114 CHD patients treated in our hospital were randomly and equally divided into tirofiban group(received pure tirofiban)and combined treatment group(received tirofiban+bisoprolol),both groups were continuously treated for two weeks.Laboratory indexes,cardiac function indexes,cardiac function class improvement before and after treatment,and incidence rate of major adverse cardiovascular events(MACE)were compared between two groups.Results:Compared with tirofiban group after treatment,there were significant reductions in serum levels of oxidized glutathione hormone(GSSG)[(30.4±5.5)μmol/L vs.(28.5±4.1)μmol/L]and high sensitive C reactive protein(hsCRP)[(8.8±1.7)mg/L vs.(7.6±3.5)mg/L],and significant rise in nitric oxide(NO)level[(52.7±13.5)μmol/L vs.(61.5±17.2)μmol/L],cardiac output(CO)[(4.3±0.7)L/min vs.(4.8±0.8)L/min],stroke volume(SV)[(77.6±10.7)mlvs.(88.1±11.2)ml]and LVEF[(55.4±11.2)%vs.(62.1±11.6)%]in combined treatment group,P<0.05 or<0.01.In combined treatment group,total effective rate of cardiac function class improvement in combined treatment group was significantly higher than that of tirofiban group(96.49%vs.71.93%,P=0.001);and total incidence rate of MACE was significantly lower than that of tirofiban group(10.53%vs.35.09%,P=0.002).Conclusion:Tirofiban combined bisoprolol can significantly reduce myocardial apoptosis,improve cardiac function,reduce incidence rate of adverse cardiovascular events in CHD patients,which is worth extending.
作者 刘茂兰 LIU Mao-lan(Department of Cardiology,Second People's Hospital of Deyang City,Deyang,Sichuan,618000,China)
出处 《心血管康复医学杂志》 CAS 2020年第3期369-373,共5页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 冠心病 血管成形术 气囊 冠状动脉 替罗非班 比索洛尔 Coronary disease Angioplasty balloon coronary Tirofiban Bisoprolol
  • 相关文献

参考文献13

二级参考文献151

共引文献176

论文智能改写系统
维普数据出版直通车
投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈